Vanguard reports 5.26% stake in Chemours
Chemours Co/The received a Schedule 13G filing from Vanguard Capital Management reporting beneficial ownership of 7,903,519 shares of Common Stock (CUSIP 163851108), representing 5.26% of the class.
Rhea-AI Filing Summary
Chemours Co/The received a Schedule 13G filing from Vanguard Capital Management reporting beneficial ownership of 7,903,519 shares of Common Stock (CUSIP 163851108), representing 5.26% of the class. The filing states Vanguard has sole dispositive power over 7,903,519 shares and sole voting power over 1,129,602 shares. The filing lists Vanguard affiliates that exercise voting or dispositive power on behalf of various funds and accounts and is signed by Ashley Grim as Head of Global Fund Administration.
Positive
- None.
Negative
- None.
Insights
Vanguard reports a passive, >5% holding in Chemours (5.26%).
The filing shows Vanguard Capital Management exercises sole dispositive power over 7,903,519 shares and reports 1,129,602 shares of sole voting power. This is a standard Schedule 13G disclosure for a large passive holder.
Implications depend on Vanguard's voting coordination with affiliates; subsequent amendments or a switch to an active filer (Schedule 13D) would signal different intentions. Future filings will show any material changes.
Key Figures
Key Terms
Schedule 13G regulatory
beneficially owned financial
sole dispositive power regulatory
sole voting power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What stake does Vanguard Capital Management report in Chemours (CC)?
Is Vanguard acting as a passive investor in the Schedule 13G for CC?
Who at Vanguard signed the Chemours Schedule 13G filing?
How is Vanguard's ownership described across its affiliates in the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.